Zentalis Pharmaceuticals, Inc.
ZNTL
$1.63
-$0.12-6.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -56.47% | -32.78% | 144.45% | -8.43% | 7.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.42% | -42.09% | 7.44% | -17.99% | 11.65% |
| Operating Income | 46.42% | -52.74% | 32.11% | 17.99% | -11.65% |
| Income Before Tax | 69.47% | -574.11% | 21.94% | 27.61% | 22.23% |
| Income Tax Expenses | -- | -- | -51.85% | -187.10% | 143.97% |
| Earnings from Continuing Operations | 69.56% | -580.87% | 22.10% | 27.70% | 21.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -- | -- |
| Net Income | 69.56% | -579.53% | 22.07% | 27.68% | 21.55% |
| EBIT | 46.42% | -52.74% | 32.11% | 17.99% | -11.65% |
| EBITDA | 46.40% | -53.70% | 32.24% | 18.05% | -11.75% |
| EPS Basic | 69.96% | -574.37% | 22.55% | 28.19% | 32.87% |
| Normalized Basic EPS | 61.04% | -465.63% | -9.19% | 28.09% | 17.45% |
| EPS Diluted | 69.96% | -581.14% | 22.55% | 28.19% | 32.87% |
| Normalized Diluted EPS | 61.04% | -467.26% | -9.19% | 28.09% | 17.45% |
| Average Basic Shares Outstanding | 1.34% | 1.10% | 0.62% | 0.71% | 16.86% |
| Average Diluted Shares Outstanding | 1.34% | 0.68% | 0.62% | 0.71% | 16.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |